HISTOPATHOLOGICAL AND RISK FACTORS OF TISSUE LUNG CANCER IN IRAQ PATIENTS REVIEW ARTICLE
Keywords:
Lung cancer, HistopathologicalAbstract
The most prevalent kind of cancer, lung cancer, claims a significant number of lives every year. In a case when the cells in the body start growing out of control, it might result in cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma represent the 3 main sub-types of cancer. The most prevalent kind of cancer is adenocarcinoma, which frequently affects long-term smokers. The second most prevalent cancer type is squamous cell carcinoma, which frequently affects those with a history of sun exposure or smoking. The cultural and social environment in Iraq that promotes tobacco use is the cause of the problem. Smoking is one of the leading causes of lung cancer cases and is responsible for 90% of lung cancer fatalities. Another significant environmental risk factor for lung cancer is indoor radon exposure. The chance of developing lung cancer is doubled in the cases where there is a family history of the disease. There is a higher risk when exposed to air pollution, have a history of lung disease, receive high radiation doses, or are near chemical or industrial carcinogens. More than one type of cancer was linked to mutations of TP53 tumor suppressor gene and EGFR oncogene. The EGFR is a transmembrane tyrosine kinase receptor promoting cell survival and proliferation.
References
W. and Mitchell Adam, W.M.(2014). Gray’s anatomy for students.3rd edition. Edinburgh: Churchill Livingstone/Elsevier; pp. 167–174.05).
- Johannes, C., Schittny,(2017);.Development of the lung. Cell and Tissue Research 367(3): 427-444.
- Betts, J. and Gordon (2013). Anatomy &physiology. pp. 787–846.
-Hines EA, Sun X(2014). Tissue crosstalk in lung development.J Cell Biochem. Sep; 115(9):1469-77.
- Morrisey, E.E. and Hogan, B.L.,(2010). Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev. Cell, 18(1); 8–23.
- Standring, Susan, B. and Neil,R. (2008). Gray’s Anatomy: The Anatomical Basis of Clinical Practice (40 ed.). Edinburgh: References Churchill Livingstone/Elsevier. pp. 992–1000. ISBN 978-0-443-06684-9
- Azlin, A.H., Looi, LM and Cheah,P.L. (2014). Tissue Microarray Immunohistochemical Profiles of p53 and p RB in Hepatocellular Carcinoma and Hepatoblastoma. Asian Pac J Cancer Pre v, 15, 3959-63.
- Akihiko- Miyanaga, Kumi- Shimizu and Rintaro- Noro (2013). Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation. BioMed Central Ltd. 29 May.
- Drake Richard L., Vog l. W. and Mitchell Adam, W.M.(2014). Gray’s anatomy for students.3rd edition. Edinburgh:Churchill Livingstone/Elsevier; pp. 167–174.
- Ganter, B.G., Jakob, S.M., Takala, I.(2006) Pulmonary capillary pressure.A review. Minerva Anestesiol;72(1-2):21-36.
- Ando, K., Oki, E., Saeki, H., Yan, Z., Tsuda, Y., Hidaka, G., Kasagi, Y., Otsu, H., Kawano,H.and Kitao, H. (2015). Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer Med.; 4: 75-83.
- Pocock, Gillian; Richards(2006). Christopher D. Human physiology: the basis of medicine. (3rd ed.). Oxford: Oxford University Press. pp. 315–318,
- Pawlina, W (2015). Histology a Tex &Atlas (7th ed.). pp. 670–678. ISBN 974511-874284511-8742.
- Tamai, S.,(2009): Lung endocrine cells and their pathology. Endocrinol Pathol., 1:171-188.
- Ahmadi, G., Jiyuan, Tu.,Kiao, I., (2013). Computational fluid and particle dynamics in the human respiratory system (1st ed.). Dordrecht: Springer. pp. 23–24
-Siegel, R., D. Naishadham, and A. Jemal, (2012). Cancer statistics, 2012, CA Cancer J. Clin. 62(1) 10–12.
- Travis, W.D., Brambilla, E. and Riely, G.J., (2013). New pathologic classification of lung Cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 10;31(8):992-1001.
- Muller, P.A. and Vousden, K.H.,(2013). p53 mutations in cancer. Nat Cell Biol.; 15(1):2-8.
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R. (2014). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer;.
- Torre, L.A., Siegel, R.L., Jemal, A.,(2016). Lung Cancer Statistics. Adv Exp Med Biol;893:1-19.
-Khoshnaw, Najmaddin, Hazha A. Mohammed, and Dana A. Abdullah(2015). “Patterns of cancer in Kurdistan-results of eight years cancer registration in Sulaymaniyah Province-Kurdistan-Iraq.” Asian Pac J Cancer Prev 16: 8525-8531.
-Ali Abdul Hussein, S. AL-Janabi, Zhoor, H. Naseer and Thuha,A. Hamody,(2017).Epidemiological Study of Cancers in Iraq-Karbala from 2008 to 2015. International Journal of Medical Research & Health Sciences, 6(1): 79-86.
- Abdulwahab, A. R. Al-Faluji, Salih, H.A., Arkan, A. and Jasem Al-Esawi.(2012). “Incidence of cancer in Fallujah above 10 years ago, with over view of common cancers in 2011.” Published DOI:10.4236/ Health..49092
- Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M. (2010) Esti¬mates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.;127:2893–2917.
- Hodkinson, PS & Sethi, T., (2011). Advances in the prevention and treatment of lung cancer. J R Coll Physicians Edinb. Jun;41(2):142-9.
- Garcia, M., Jemal, A., Ward, E.M., (2007). Global cancer facts & figures 2007.Atlanta, GA: American Cancer Society 2007.
-Mosavi-Jarrahi,A., Gouya, M.M. and Ramazani, R., (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
-Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Waldron,W., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner,M.P., Lewis, D.R., Chen, H.S., Feuer, E.J.and Cronin, K.A. (eds).(2012). SEER Cancer Statistics Review, 1975-2009. Bethesda, MD: National Cancer Institute.
- Zheng, R., Zeng, H., Zhang, S., Chen, T., Chen, W.,(2016). National estimates of cancer prevalence in China, 2011Cancer letters.; 370(1):33–8.
- Zeng, H., Zheng, R., Guo, Y., Zhang, S., Zou, X. and Wang, N., (2015)Cancer survival in China, 2003China, 2011Cancer-based study. International Journal of Cancer.; 136(8):1921–30.
-Siegel, R.L., Miller,K.D. and Jemal, A.,(2015). Cancer statistics, 2015. CA: a cancer journal for clinicians.; 65(1):5–29.
- De- Angelis, R., Sant, M., Coleman,M.P., Francisci S., Baili, P., and Pierannunzio, D., (2014). Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. The lancetoncology.; 15(1):23–34.
-Siegel, R.L., Miller, K.D. and Jemal, A.,(2017). Cancer Statistics, 2017. CA Cancer J Clin;67:7-30.
- Sun, S., Schiller, J.H. and Gazdar, A.F.,(2007). Lung cancer in never smokers–a different disease. Nat Rev Cancer;7:778 –790.
- Shaper, A.G., Wanname thee, SG and Walker, M.,(2003). Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men. Int J Epidemiol;32(5):802–808.
- Henley SJ, Thun MJ, Chao Aand Calle EE(2004). Association between exclusive pipe smoking and mortality from cancer and other diseases. J Natl Cancer Inst;96(11):853–861.
-Khuder, S.A., (2001). Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 31:139-148.
-Ezzati, M.& Lopez, A.D.,(2003). Estimates of global mortality attributable to smoking in 2000. Lancet.;362:847–852.
- Atlanta, GA (2004):US Dept of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention.
- Jha,P., Ramasundarahettige, C., Landsman,V., Rostron, B., Thun, M., Anderson. RN, Mcafee, T.and Peto, R., (2013).21-st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med.;368:341–35.
- Yang, L., Parkin,D.M., Li,L.and Chen, Y.,(2003). Time trends in cancer mortality in China: 1987–1999. Int J Cancer;106:771–783.
- Li, C. Wang, Lei,W., Sabrina, K., Jennifer, A. W., Li, Q. Wu., Hong, Z., Li Z. Z, Na, L. S., and Lei, Z., (2011).” Analysis on the clinical features of 22 basaloid squamous-cell carcinoma of the lung”.Journal of Cardiothoracic Surgery,; 6(10).
- Parkin, D.M., Bray, F., Ferlay, J., Pisani, P. and Parkin, D.M.,(2005). Global cancer statistics, 2002. CA Cancer J Clin.;55:74–108.
- Saika, K. and Machii, R.,(2012). Cancer mortality attributable to tobaccoby region based on the WHO Global Report. Jpn J Clin Oncol.;42:771–772.
- Saccone, S.F., Hinrichs, A.L. and Saccone, N.L., (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet;16:36-49
-Benowitz, N.L.(2008). Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther;83:531-41.
-Costa, F.& Soares, R.,(2009). Nicotine: a pro-angiogenic factor. Life Sci;84:785-90.
-Hecht, S. (2003). Tobacco carcinogens, their biomarkers and-tobacco-induced cancer. Nat Rev Cancer, 3, 733-44.
- Sopori, M., (2002). Effects of cigarette smoke on the immune-system. Nature reviews. Immunology, 2, 372-7.
-Torre, L.A., Siegel, R.L., Jemal, A.,(2016). Lung Cancer Statistics. Adv Exp Med Biol;893:1-19.
-Torre, L.A., Siegel, R.L., Jemal, A.,(2016). Lung Cancer Statistics. Adv Exp Med Biol;893:1-19.
-Shamseddine, A., Saleh, A., Charafeddine, M., Seoud, M., Mukherji, D. and Temraz, S., (2014).Cancer trends in Lebanon: a review of incidence rates for the period of 2003–2008 and projections until 2018. Popul Health Metrics;12:4.
-Siegel,R.L., Miller, K.D., Jemal, A.,(2018). Cancer statistics, 2018. CA Cancer J Clin;68:7-30..
- Patel, J.D., (2005). Lung cancer in women. J Clin Oncol;23:3212-8.
- Planchard,D., Loriot, Y. and Goubar, A., (2009). Differential expression of biomarkers in men and women. Semin Oncol;36:553-65.
- Matakidou, A., Eisen, T. and Houlston, R.S., (2005). Systematic review of the relationship between family history and lung cancer risk. Br J Cancer;93:825– 833.
- Nitadori, J., Inoue, M., Iwasaki, M., (2006). Association between lung cancerincidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC Study. Chest;130:968–975.
- Schwartz,A.G. and Ruckdeschel, J.C.,(2005): ir pollutionfrom lung to heart. Swiss Med Wkly;135(47–48):697–702
- Vineis, P. and Husgafvel-Pursiainen, K.,(2005). Air pollution and cancer: biomarker studies in human populations.Carcinogenesis 2005 Nov;26(11):1846–1855.
- Boffetta, P.(2006). Human cancer from environmental pollutants: the epidemiological evidence. Mutat Res2006 Sep 28;608(2):157–162.
- Govindan,R., and Subramanian, J. (2007). Lung cancer in never smokers: a review J Clin Oncol;25:561–570.
- De- Matteis, S., Consonni, D., Bertazzi, P.A.,(2008). Exposure to occupational carcinogens and lung cancer risk. Evolution of epidemiological estimates of attributable fraction. Acta Biomed;79 Suppl 1:34-42.
- Dela –Cruz, C.S., Tanoue, T.L.and Matthany, R.A,.(2009). Lung Cancer: Epidemiology and Carcinogenesis. In: Shields TW, editor. General Thoracic Surgery. 7th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins,:1281-98.
- Alberg, A.J., Brock,M.V., Ford, J.G., Samet,J.M. and Spivack, S.D. (2013). Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest;143:e1S-29S.
- Alberg, Rex, C. Yung, Paul Timothy Strickl and, Jonas Nelson (2002). Respiratory cancer and exposure to arsenic, chromium, nickel and polycyclic aromatic hydrocarbons. Clin Occup Environ Med;2:779-801.
- Torok, S.1., Hegedus, B., Laszlo, V., Hoda,M.A., Ghanim, B., Berger, W., Klepetko, W., Dome, B. and Ostoros, G., (2011). Lung cancer in never smokers. Future Oncol;7:1195-211.
- Lee, Y.J., Kim, J.H., Kim, S.K., Ha, S.J., Mok,T.S., Mitsudomi, T. and Cho, B.C., (2011). Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer;72:9-15.
- Wakelee, H.A., Chang, E.T., Gomez, S.L., Keegan, T.H., Feskanich, D., Clarke, C.A., Holmberg, L.and Yong, L.C., (2007). Lung cancer incidence in never smokers. J Clin Oncol;25:472– 478.
- Brenner, D.R., McLaughlin, J.R., Hung, R.J,(2011). Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One;6:e17479.
- Krewski,D.1., Lubin, J.H., Zielinski, J.M., Alavanja,M., Catalan, V.S., Field, R.W., Klotz, J.B., Létourneau,E.G. and Lynch, C.F. (2005). Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology;16:137-45
- Turner,M.C., Krewski,D., Chen, Y., Pope, C.A., Gapstur,S.M. and Thun, M.J., (2012). Radon and COPD mortality in the American Cancer Society Cohort. Eur Respir J;39:1113-9
- Ruano-Ravina, A., Figueiras, A. and Barros-Dios,J.M.,(2010). Diet and lung cancer: a new 45- De Stefani E, Fontham ET, Chen V, et al. Fatty foods and the risk of lung cancer: a case-control study from Uruguay. Int J Cancer.;71(5):760–766.
-De Stefani E, Fontham ET, Chen V, et al. Fatty foods and the risk of lung cancer: a case-control study from Uruguay. Int J Cancer.;71(5):760–766.
- Goodman, M,T., Kolonel, L.N. and Yoshizawa, CN, (2011). The effect of dietary cholesterol and fat on the risk of lung cancer in Hawaii. Am J Epidemiol.;128(6):1241–1255
- Lissowska,J., Foretova, L., Dabek, J., Zaridze, D., Szeszenia-Dabrowska, N., Rudnai,P., Fabianova, E. and Cassidy, A., (2010). Family history and lung cancer risk: international multi centre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes control;21:1091-104.
- Azzoli, C. G.S.,Baker, Jr. S., Temin, (2009). “American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer,” Journalof Clinical Oncology, vol. 27, no. 36, pp. 6251–6266.
- Travis, W. D., Brambilla,E. and Burke, A.P., (2010). Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization.WHO press,;7(7): 412 pages
- Travis,W.D., Noguchi, M., Yatabe, Y., Brambilla, E.,Nicholson, A.G., Aisner, S.C., Austin, J.H.M., Devesa,S.S., Hirsch, F.R., Ladanyi, M., Meyerson, M., Mino-Kenudson, M., Powell, C.A., Rami-Porta, E., Rekhtman, N., Riely, G., Russell, P., Samet, J., Scagliotti, G.,Thunnissen, E., To, K.F., Tsuta, K., van –Schil, P.,Warth, A., Wistuba, I.I. and Yankelevitz, D., (2015). Adenocarcinoma. In: WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart. Sep;10(9):1240-1242.
- Barletta, J.A., Yeap, B.Y., Chirieac, L.R.(2010). Prognostic significance of grading in lung adenocarcinoma. Cancer;116:659–669. Pawlina, W.Histology a Text & Atlas. 7th edition, pp. 670–678.
- Lane, D. and Levine, A.(2010). p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol.; 2(12).
- Szymanska, K.; Hainaut, P.,(2003). TP53 and mutations in human cancer.Acta Biochim. Pol., 50 (1), 231–8.
- Dumont, P., Leu, J.I., Della, P.A., George, D.L. and Murphy, M.,(2003). The codon 72polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet;33:357 – 65.
- Zhou, J. and Ben, S.,(2018). Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. Thorac Cancer;9:228-33.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
